Before taking Cibinqo(abrocitinib)

Abrocitinib tablets are a Class 1 innovative drug developed by Pfizer, with the main ingredient abrocitinib. It is indicated for the treatment of adults and pediatric patients aged 12 years and older with refractory moderate-to-severe atopic dermatitis. Patients should pay attention to the following precautions when taking the medication:】

Precautions for Abrocitinib Tablets (CIBINQO) 

Serious infections, viral reactivation, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thromboembolism, laboratory abnormalities, and vaccination, etc.